Plavix combination drug market emerging as blue chip

Published: 2010-12-22 07:00:00

Updated: 2010-12-22 07:00:00

Many major Korea pharmaceutical manufacturers are poised to introduce a combination product of Plavix and Aspirin (clopidogrel + acetylsalicylate 75 mg) with the hope of acquiring large share of the blockbuster drug as the Korea unit of Sanofi Aventis announced its intention not to develop the co...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK